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The worldwide prevalence of obesity and related metabolic disorders is rising rapidly, increasing the burden on our healthcare
system. Obesity is often accompanied by excess fat storage in tissues other than adipose tissue, including liver and skeletal muscle,
which may lead to local insulin resistance and may stimulate inflammation, as in steatohepatitis. In addition, obesity changes the
morphology and composition of adipose tissue, leading to changes in protein production and secretion. Some of these secreted
proteins, including several proinflammatory mediators, may be produced by macrophages resident in the adipose tissue. The
changes in inflammatory status of adipose tissue and liver with obesity feed a growing recognition that obesity represents a state
of chronic low-level inflammation. Various molecular mechanisms have been implicated in obesity-induced inflammation, some
of which are modulated by the peroxisome proliferator-activated receptors (PPARs). PPARs are ligand-activated transcription
factors involved in the regulation of numerous biological processes, including lipid and glucose metabolism, and overall energy
homeostasis. Importantly, PPARs also modulate the inflammatory response, which makes them an interesting therapeutic target
to mitigate obesity-induced inflammation and its consequences. This review will address the role of PPARs in obesity-induced
inflammation specifically in adipose tissue, liver, and the vascular wall.
Copyright © 2007 Rinke Stienstra et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
The prevalence of obesity worldwide has progressively in-
creased over the past decades. In 2000, it was estimated that
more than half of US adults were overweight, while the fre-
quency of obesity, which is defined by a body mass index
(BMI) ≥ 30 kg/m2, was 20%, reflecting an increase of 61%
within 10 years [1]. Not only have more and more adults be-
come obese, obesity is also striking at a much younger age
leading to a high number of obese children and adolescents
[2]. Unless drastic action is taken, many countries will face a
decline in life expectancy in the 21st century due to the obe-
sity epidemic.
Obesity is the direct result of an imbalance between en-
ergy intake and energy expenditure. The excess energy is
primarily stored in adipose tissue in the form of triglyc-
erides. Although adipocytes are specifically designed to
store energy and easily fill up with fat, the morphological
changes associated with adipose tissue growth are not with-
out consequences for the organism as a whole [3]. Evidence
has accumulated suggesting that in response to adipocyte
hypertrophy during development of obesity, adipose tissue
function is compromised.
Obesity also provokes structural and metabolic alter-
ations in other organs, including skeletal muscle and liver.
Indeed, obesity is closely linked to fat storage in liver and
is nowadays considered as a major risk factor for the de-
velopment of fatty liver diseases. The incidence of nonalco-
holic fatty liver disorders (NAFLDs) and obesity are there-
fore intimately linked. It has been estimated that about 75%
of obese subjects have NAFLD while 20% develop nonalco-
holic steatohepatitis (NASH), which is defined as fatty liver
disease with inflammation [4]. The amount of fat stored in
liver is determined by the balance between fatty acid uptake,
endogenous fatty acid synthesis, triglyceride synthesis, fatty
acid oxidation, and triglyceride export. Changes in any of
these parameters can aﬀect the amount of fat stored in liver.
The excessive fat accumulation in adipose tissue, liver,
and other organs strongly predisposes to the development
of metabolic changes that increase overall morbidity risk.
The metabolic abnormalities that often accompany obesity
include hypertension, impaired glucose tolerance, insulin
resistance leading to hyperinsulinemia, and dyslipidemia.
Collectively, these abnormalities have been clustered into the
metabolic syndrome or Syndrome X [5]. Individuals that
are diagnosed with metabolic syndrome have a significantly
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increased risk of developing cardiovascular disease (CVD)
and type II diabetes. Inasmuch as CVD is the major cause of
death in industrialized countries, eﬀective strategies to cur-
tail the number of individuals with metabolic syndrome are
badly needed. Visceral obesity, which is characterized by ex-
cess fat storage in and around the abdomen, is the prime
cause of the metabolic abnormalities, and therefore repre-
sents an important target in the treatment of metabolic syn-
drome [6].
In recent years, it has become clear that obesity also gives
rise to a heightened state of inflammation. The link between
obesity and inflammation was first established by Hotamis-
ligil et al. who showed a positive correlation between adi-
pose mass and expression of the proinflammatory gene tu-
mor necrosis factor-α (TNFα) [7]. The link between obe-
sity and inflammation has been further illustrated by the in-
creased plasma levels of several proinflammatory markers in-
cluding cytokines and acute phase proteins like C-reactive
protein (CRP) in obese individuals [8, 9]. Nowadays, CRP
is considered as an independent biomarker for the develop-
ment of CVD [10] which emphasizes the connection between
inflammation, obesity, and CVD. Many of the inflammatory
markers found in plasma of obese individuals appear to orig-
inate from adipose tissue [8]. These observations have led to
the view that obesity is a state of chronic low-grade inflam-
mation that is initiated by morphological changes in the adi-
pose tissue.
One consequence of the elevated inflammatory status
is insulin resistance. Proinflammatory cytokines originating
from fat have been shown to directly interfere with insulin
signaling pathways [11]. For example, TNFα causes insulin
resistance by inhibiting tyrosine phosphorylation of insulin
receptor substrate-1 (IRS-1) [12]. Othermechanisms of inhi-
bition of IRS-1 phosphorylation by inflammatory mediators
include chronic activation of JNK, PKC, and IKK [13–15].
Besides TNFα, adipose tissue produces a host of other
adipokines with well-described eﬀects on metabolism and
inflammation. Resistin, adiponectin, leptin, and monocyte
chemoattractant protein-1 (MCP-1) are among a group
of secreted proteins from adipose tissue with immune-
modulating functions [16]. The production and secretion
of these adipokines are altered during obesity, resulting in a
more proinflammatory or atherogenic secretion profile. In-
deed, whereas secretion of MCP-1, resistin, and other proin-
flammatory cytokines is increased by obesity, the adipose se-
cretion of the anti-inflammatory protein adiponectin is de-
creased [17].
Although increased visceral fat depots [6] and adipocyte
hypertrophy [3] had been linked to a higher degree of adi-
pose inflammation, until recently the exact pathways leading
to a proinflammatory state of adipose tissue in obese individ-
uals remained unidentified. However, recently much atten-
tion has been diverted to the role of macrophages. In 2003,
two papers published back to back showed that diet-induced
obesity is associated with infiltration of macrophages into
white adipose tissue [18, 19]. Infiltrated macrophages, which
are part of the stromal vascular fraction of adipose tissue, are
subsequently responsible for the production of a wide vari-
ety of proinflammatory proteins including MCP-1, TNFα,
and interleukin-6 (IL-6). The development of insulin resis-
tance in adipocytes was closely linked to the infiltration of
macrophages. However, if and how entry of macrophages
into white adipose tissue (WAT) leads to systemic insulin re-
sistance remains unclear, although it is increasingly believed
that altered secretion of adipokines by WAT during obesity
may represent an important piece of the puzzle.
One of the other tissues that is aﬀected by the enlarge-
ment and proinflammatory secretion profile of adipose tis-
sue is the liver. Chronic activation of the master regulator
of inflammation nuclear factor-κB (NF-κB) by cytokines has
been directly linked to the development of insulin resistance
in liver [20, 21]. It has also been shown that adipose-specific
overexpression of MCP-1 increases hepatic triyglyceride con-
tent [22]. Although steatosis is a common occurrence in
obese individuals, the role of inflamed adipose tissue in de-
velopment of steatosis needs further exploration.
Initially characterized by excess fat storage, steatosis can
progress to steatohepatitis and finally leads to cirrhosis and
structural alterations of the liver [23]. The molecular mech-
anisms underlying the development of steatosis and progres-
sion to steatohepatitis remain poorly understood. Whereas
some patients only develop steatosis, others develop steato-
hepatitis and fibrosis. Lipid peroxidation, cytokines, and
other proinflammatory compounds are believed to play a vi-
tal role in the transition [4]. In addition, the role of the ex-
panding adipose tissue might also prove relevant to the de-
velopment of steatohepatitis.
Recently, the elevated inflammatory status of adipose tis-
sue and concurrent increased production of adipose tissue-
derived cytokines have also been connected with atheroscle-
rosis. Initially defined as a pathological lipid deposition, the
atherosclerotic process is nowadays considered as an on-
going inflammatory process in which numerous cytokines,
chemokines, and inflammatory cells participate [24]. Inde-
pendent of its connection to the metabolic syndrome, obe-
sity itself is a known risk factor for the development of
atherosclerosis and CVD [25].
In summary, obesity represents amajor health threat, and
eﬀective therapies to minimize obesity-related comorbidi-
ties are sorely needed. By targeting the inflammatory com-
ponent, the progression of obesity towards insulin resistance
and CVD might be slowed down.
The ligand-activated transcription factors belonging to
the peroxisome proliferators- activated receptor (PPAR)
family are involved in the regulation of inflammation and en-
ergy homestasis and represent important targets for obesity,
obesity-induced inflammation, and metabolic syndrome in
general. These receptors share a common mode of action
that involves heterodimerization with the nuclear receptor
RXR and subsequent binding to specific DNA-response el-
ements in the promoter of target genes. Binding of ligands to
PPARs leads to recruitment of coactivators and chromatin
remodeling, resulting in initiation of DNA transcription
[26, 27]. Currently, synthetic PPAR agonists are widely used
for the treatment of insulin resistance and dyslipidemia. This
review will explore the role of PPARs in governing chronic
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inflammation with special emphasis on the connection with
metabolic syndrome. The link with obesity and inflamma-
tion will be discussed separately for the three PPAR isoforms:
PPARα, PPARβ/δ, and PPARγ.
2. PPARα
PPARα is well expressed in metabolically active tissues in-
cluding liver, brown adipose tissue, muscle, and heart. In
addition, PPARα is expressed in cells involved in immune
responses including monocytes, macrophages, and lympho-
cytes [28]. Activation of PPARα occurs through a variety
of natural agonists, including unsaturated fatty acids and
eicosanoids, whereas fibrate drugs act as synthetic agonists.
In liver, PPARα plays a pivotal role in fatty acid catabolism
by upregulating the expression of numerous genes involved
in mitochondrial fatty acid oxidation, peroxisomal fatty
acid oxidation, and numerous other aspects of fatty acid
metabolism in the cell [28]. As a consequence, activation of
PPARα can prevent and decrease hepatic fat storage [29–32].
Other metabolic pathways under control of PPARα include
gluconeogenesis [33], biotransformation [34], and choles-
terol metabolism [35]. While the function of PPARα in
mouse liver is relatively well defined, much less is known
about its role in human liver. Experiments with “humanized”
PPARαmice have revealed that there are intrinsic diﬀerences
in the properties of the human and mouse PPARα protein
[36]. In general, research on the role of PPARα in human
liver is hampered by the low expression levels of PPARα in
human hepatoma cell lines [37].
Besides governing metabolic processes, PPARα also reg-
ulates inflammatory processes, mainly by inhibiting inflam-
matory gene expression. Hepatic PPARα activation has been
repeatedly shown to reduce hepatic inflammation elicited
by acute exposure to cytokines and other compounds. In
recent years, several molecular mechanisms responsible for
the immunosuppressive eﬀects of PPARα have been uncov-
ered [38]. These include interference with several proin-
flammatory transcription factors including signal transducer
and activator of transcription (STAT), activator protein-1
(AP-1), and NF-κB by PPARα [39]. The latter mechanism
involves stimulation of expression of the inhibitory pro-
tein IκBα, which retains NF-κB in a nonactive state, lead-
ing to suppression of NF-κB DNA-binding activity [40]. De-
tailed molecular studies have further revealed that PPARα
diminishes the activity of the proinflammatory transcrip-
tion factor CAATT/enhancer binding proteins (C/EBP) via
sequestration of the coactivator glucocorticoid receptor-
interacting protein-1/transcriptional intermediary factor-2
(GRIP1/TIF2) [41]. Finally, PPARα can also inhibit cytokine
signaling pathways via downregulation of the IL-6 receptor
[42] and upregulation of sIL-1 receptor antagonist [Stien-
stra et al., in press], leading to diminished inflammatory re-
sponses. Interestingly, in humans, specific PPARα activation
using fenofibrate has been shown to decrease plasma levels
of several acute phase proteins that are normally increased
during inflammatory conditions [42].
2.1. PPARα and steatosis
In mice fed a high-fat diet, proper functioning of PPARα is
essential to prevent the liver from storing large amounts of
fat [43]. By inducing mitochondrial, peroxisomal, and mi-
crosomal fatty acid oxidation, PPARα reduces hepatic fat ac-
cumulation in the liver during the development of fatty liver
disease, and thus prevents steatosis [31, 44, 45]. It can be hy-
pothesized that since PPARα has a potent anti-inflammatory
activity in liver, the progression of steatosis towards steato-
hepatitis might be counteracted by PPARα. Indeed, several
studies in mice have shown that PPARα activation is able to
reduce or even reverse steatohepatitis induced by feeding a
methionine- and choline-deficient (MCD) diets [31, 45, 46].
In a mouse model of steatohepatitis, the presence and
activation of PPARα prevented the induction of COX-2 ex-
pression [47]. Since upregulation of COX-2 is seen in alco-
holic steatohepatitis and nonalcoholic steatohepatitis and has
been directly linked to the progression of steatosis to steato-
hepatitis, the inhibitory eﬀect of PPARα on COX-2 may re-
duce steatohepatitis. An anti-inflammatory role of PPARα
in the development of steatohepatitis is further supported
by a study in which wild-type and PPARα −/− mice were
fed a high-fat diet to induce obesity. Although both geno-
types developed a fatty liver after chronic high-fat feeding,
animals lacking PPARα developed steatohepatitis accom-
panied by an increased number of infiltrated lymphocytes
and macrophages. By suppressing the expression of specific
chemokines involved in attracting macrophages and other
immune-related cell types, PPARα might moderate steato-
hepatitis [Stienstra et al., submitted]. These results are in
line with a study performed in APOE2 knock-in mice fed
a western-type high-fat diet [48]. When the animals were
cotreated with fenofibrate, macrophage infiltration of the
liver was prevented.
2.2. PPARα and atherosclerosis
Inflammation in the arterial wall is known to promote the
process of atherosclerosis [49]. In addition to suppressing
the inflammatory response in liver, PPARα may also influ-
ence inflammatory reactions in the arterial wall. As PPARα is
expressed in various cell types present in atherosclerotic le-
sions, the eﬀect of PPARα on lesion development is rather
complex. Immune-modulating eﬀects of specific PPARα ac-
tivation have been reported in various cell types. However,
some controversy still exists about the exact role of PPARα in
the vascular wall as both pro- and antiatherogenic eﬀects of
PPARα have been demonstrated.
An antiatherogenic eﬀect of PPARα via suppression of
several proinflammatory genes like MCP-1, TNFα, vascu-
lar cell adhesion molecule-I (VCAM I), intercellular ad-
hesion molecule-I (ICAM I), and interferon-γ (IFNγ) has
been reported in the vascular wall of animals with extensive
atherosclerosis [50]. Other studies have shown that the anti-
inflammatory role of PPARα in the vascular wall seems to be
dependent on the severity of inflammation or vascular lesion.
In the absence of inflammation or in early lesions, the eﬀects
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of PPARα are mainly proatherogenic [51, 52], whereas the
development of severe lesions accompanied by inflammation
is strongly reduced by PPARα activation.
Several acute phase proteins have been linked to the de-
velopment of atherosclerosis [53]. This includes CRP, which
is currently used as a marker for systemic inflammation and
linked to CVD, and serum amyloid A (SAA), which has been
shown to be involved in the development of atherosclerosis
[54]. As PPARα activation downregulates plasma concentra-
tions of acute phase proteins including CRP and SAA in hu-
mans [42], it might indirectly prevent or slow down the pro-
gression of atherosclerosis.
2.3. PPARα and adiposity
Although expression of PPARα in WAT is much lower com-
pared to PPARγ, evidence abounds that PPARα may also
influence adipose tissue function. It has been shown that
PPARα−/−mice gain more adipose mass compared to wild-
type animals [55], which may be via local or systemic eﬀects
of PPARα. An antiobesity role for PPARα is supported by sev-
eral studies in which obese rodents were administered syn-
thetic PPARα agonists [56–58]. While it is true that PPARα
agonists have a clear anorexic eﬀect resulting in decreased
food intake, evidence is accumulating that PPARα may also
directly influence adipose tissue function, including its in-
flammatory status.
A recent study revealed that treatment of obese diabetic
KKAy mice with Wy-14643 decreased adipocyte hypertrophy
as well as macrophage infiltration [59]. In PPARα −/− mice
chronically fed a high-fat diet (HFD), expression of inflam-
matory genes in adipose tissue was more pronounced com-
pared to wild-type mice. In addition, fractionation of adi-
pose tissue in adipocytes and stromal vascular cells revealed
higher gene expression levels of the specific macrophage
marker F4/80+ in the stromal vascular fraction of PPARα
−/−mice [Stienstra et al., submitted].
PPARα may govern adipose tissue inflammation in three
diﬀerent ways: (1) by decreasing adipocyte hypertrophy,
which is known to be connected with a higher inflammatory
status of the tissue [3, 11, 59], (2) by direct regulation of in-
flammatory gene expression via locally expressed PPARα, or
(3) by systemic events likely originating from liver. Full clar-
ification of the role of locally expressed PPARα in adipose
tissue will have to await the availability of adipose tissue-
specific PPARα −/−mice.
Thus, while evidence is mounting that PPARα activation
reduces adipose inflammation as observed during obesity, it
is unclear whether the anti-inflammatory eﬀects of PPARα in
WAT are caused by direct or indirect mechanisms.
3. PPARβ/δ
Compared to PPARα and PPARγ, much less is known about
PPARβ/δ and its natural ligands. Due to its ubiquitous ex-
pression profile, lack of specific ligands and, until recently,
lack of availability of knock-out models, the role of PPARβ/δ
inmany tissues has been poorly explored. Fortunately, the re-
cent generation of PPARβ/δ −/−mice has provided a strong
impetus for the characterization of the function of PPARβ/δ
[60]. Several abnormalities have been observed in mice lack-
ing PPARβ/δ which include impaired wound healing, a de-
crease in adipose mass, and disturbed inflammatory reac-
tions in skin [61].
PPARβ/δ has been directly linked to the development of
obesity. Indeed, several groups have reported a decrease in
adiposity after PPARβ/δ activation. By stimulating fatty acid
oxidation, PPARβ/δ activation leads to loss of adipose mass
in diﬀerent mouse models of obesity [62]. Similar eﬀects on
fatty acid oxidation have been observed in heart, resulting in
improved muscle contraction [63]. In addition to increasing
fatty acid oxidation, activation of PPARβ/δ in muscle also
increases the number of type I muscle fibers, which leads to
enhanced endurance performance [64].
The number of studies that have addressed the role
of PPARβ/δ during inflammation is limited. So far, an
anti-inflammatory eﬀect has been observed in macrophages
suggesting a possible role for PPARβ/δ in the process of
atherogenic inflammation. It appears that PPARβ/δ acts as
an inflammatory switch in which inactivated PPARβ/δ is
proinflammatory and activated PPARβ/δ promotes an anti-
inflammatory gene expression profile. The proposed switch
of PPARβ/δ is linked to the B cell lymphoma-6 (BCL-6)
protein which functions as inflammatory suppressor pro-
tein [65]. In the unliganded state, BCL-6 is part of the
PPARβ/δ-RXRα transcriptional complex. Upon ligand ac-
tivation, corepressors including BCL-6 are dissociated and
PPARβ/δ-dependent gene transcription ensues. The released
BCL-6 subsequently acts as a repressor of proinflammatory
gene expression in macrophages.
3.1. PPARβ/δ and steatosis
It can be hypothesized that the stimulatory eﬀect of PPARβ/δ
on fatty acid oxidation in muscle and adipose tissue might
also extend to liver, which would render PPARβ/δ an anti-
steatotic role in liver. Within the liver, PPARβ/δ expression
is found in diﬀerent cell types although the highest levels are
found in hepatic endothelial cells [66].
According to a recent report by Nagasawa et al., acti-
vation of PPARβ/δ may diminish fatty liver disease. In this
study, mice were fed an MCD diet to induce steatohepatitis.
Administration of the PPARβ/δ agonist GW501516 not only
decreased hepatic lipid content, yet it also reduced inflamma-
tory gene expression. PPARβ/δ decreased fat storage in liver
mainly by activation of genes involved in fatty acid oxida-
tion. Furthermore, the elevatedmRNA levels of transforming
growth factor-β1 (TGF-β1), TNFα, MCP-1 and interleukin-
1β (IL-1β) that accompany the development of steatohep-
atitis were counteracted by PPARβ/δ activation [67]. Which
liver cell types and molecular mechanisms contribute to the
observed regulation is unknown.
3.2. PPARβ/δ and atherosclerosis
Due to the anti-inflammatory properties of PPARβ/δ in
macrophages, it is plausible that atherosclerosis is aﬀected
by PPARβ/δ-activation. By feeding low-density lipoprotein
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receptor (LDLR) −/−mice a hypercholesterolemic diet sup-
plemented with a specific PPARβ/δ ligand, it was shown that
PPARβ/δ is able to interfere with the inflammatory process
underlying the development of atherosclerosis. Whereas le-
sion development itself was not prevented by PPARβ/δ ac-
tivation, inflammatory gene expression was blunted com-
pared to untreated mice [50]. The anti-inflammatory ac-
tion of PPARβ/δ was mainly achieved by a strong inhibi-
tion of VCAM-1, MCP-1, and IFN-γ expressions, genes that
are associated with the development of atherosclerosis. A re-
cent study in which LDLR −/− mice were treated with the
PPARβ/δ agonist GW0742X revealed an antiatherosclerotic
eﬀect of PPARβ/δ, in addition to an anti-inflammatory ef-
fect. Lesion development was strongly inhibited and inflam-
matory gene expression in macrophages was decreased [68].
While in mice there is compelling evidence for an anti-
inflammatory role of PPARβ/δ in the atherosclerosis, the role
of PPARβ/δ in humans is relatively unknown. Remarkably,
PPARβ/δ was shown to strongly promote lipid accumula-
tion in human macrophages, thereby supporting the devel-
opment of atherosclerosis [69].Whether PPARβ/δ influences
inflammatory gene expression in human cells needs further
study.
3.3. PPARβ/δ and adiposity
Recently, it was shown that activation of PPARβ/δ in adipose
tissue causes a marked decrease in fat mass which is mainly
achieved by activation of fatty acid oxidative pathways [62].
Moreover, high-fat-diet-induced adiposity was strongly in-
hibited by activation of PPARβ/δ in adipose tissue. Whether
PPARβ/δ is able to control inflammatory gene expression in
WAT during diet-induced obesity is still unclear. Inasmuch as
inflammatory gene expression is linked to adiposity, it could
be hypothesized that inflammatory gene expression will be
suppressed by PPARβ/δ activation. Also, since expressions
of IL-1β, MCP-1, and TNFα are controlled by PPARβ/δ in
liver [67], it is tempting to speculate that inflammatory gene
expression is under control of PPARβ/δ in adipose tissue as
well.
4. PPARγ
PPARγ is considered the master regulator of adipogenesis,
and accordingly has been extensively studied in the context of
obesity. In humans, PPARγ is most highly expressed in adi-
pose tissue, yet reasonable levels of PPARγmRNA can also be
found in other organs including skeletal muscle, colon, and
especially lung [70]. The latter is probably due to the abun-
dance of macrophages in lung. At least two diﬀerent isoforms
of PPARγ are known: PPARγ1, which is the form expressed
in nonadipose tissues, and PPARγ2, which is adipose-tissue
specific. Unsaturated fatty acids and several eicosanoids serve
as endogenous agonists of PPARγ, while antidiabetic drugs
belonging to the thiazolidinediones act as synthetic agonists
of PPARγ. Target genes of PPARγ are involved in adipocyte
diﬀerentiation, lipid storage, and glucose metabolism, and
include lipoprotein lipase, CD36, phosphoenolpyruvate car-
boxykinase, aquaporin 7, and adiponectin [71].
Gain and loss of function studies have shed more light on
the specific functions of PPARγ in diﬀerent tissues.While ho-
mozygous PPARγ-deficient animals are embryonically lethal,
specific ablation in adipose tissue revealed the indispensable
role of PPARγ in adipocyte diﬀerentiation and function [72].
In liver, PPARγ is involved in triglyceride homeostasis and
contributes to steatosis. At the same time, hepatic PPARγ
protects other tissues from triglyceride accumulation and in-
sulin resistance [73].
Similar to PPARα, PPARγ is involved in governing the in-
flammatory response, especially in macrophages. Currently,
two diﬀerent molecular mechanisms have been proposed
by which anti-inflammatory actions of PPARγ are eﬀectu-
ated: (1) via interference with proinflammatory transcrip-
tion factors including STAT, NF-κB, and AP-1 [74], and (2)
by preventing removal of corepressor complexes from gene
promoter regions resulting in suppression of inflammatory
gene transcription [75]. This mechanism involves ligand-
dependent SUMOylation of PPARγ followed by binding
of PPARγ to nuclear receptor corepressor (NCoR)-histone
deacetylase-3 (HDAC3) complexes localized on inflamma-
tory gene promoters. The binding of PPARγ prevents the
removal of corepressor complexes, thus retaining inflamma-
tory genes in a suppressed state.
4.1. PPARγ and adiposity
PPARγ is indispensable for adipocyte diﬀerentiation both in
vivo and in vitro [76–78]. In spite of its vital role in adi-
pogenesis and lipogenesis, PPARγ expression itself is not
strongly influenced during obesity. As discussed above, diet-
induced obesity is associated with increased inflammatory
gene expression in adipose tissue via adipocyte hypertro-
phy and macrophage infiltration. It has been shown that
PPARγ is able to reverse macrophage infiltration, and subse-
quently reduces inflammatory gene expression [18]. Adipose
expression of inflammatory markers A disintegrin and met-
allopeptidase domain-8 (ADAM8), macrophage inflamma-
tory protein-1α (MIP-1α), macrophage antigen-1 (MAC-1),
F4/80+, and CD68 was downregulated by specific PPARγ
activation. Inflammatory adipokines mainly originate from
macrophages which are part of the stromal vascular frac-
tion of adipose tissue [18, 19], and accordingly, the down-
regulation of inflammatory adipokines in WAT by PPARγ
probably occurs via eﬀects on macrophages. By interfering
with NF-κB signaling pathways, PPARγ is known to de-
crease inflammation in activated macrophages [74]. PPARγ
may also influence inflammatory gene expression via ef-
fects on adipocyte morphology. Indeed, smaller adipocytes
are known to secrete less inflammatory markers compared
to larger adipocytes [3]. Treatment of obese rats with the
synthetic PPARγ agonist troglitazone dramatically reduced
the size of adipocytes without changing the total weight of
WAT. In parallel, the expression levels of the inflammatory
marker TNFα were normalized compared to those of un-
treated rats [79]. Furthermore, by inducing the expression
of adiponectin in adipocytes [80], PPARγ may directly con-
tribute to suppression of chronic inflammation accompany-
ing obesity.
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Summarizing, the anti-inflammatory eﬀects of PPARγ
activation in adipose tissue are presumably achieved by
eﬀects on both adipocytes and adipose tissue-resident
macrophages. Interestingly, PPARγ is induced both dur-
ing macrophage and adipocyte diﬀerentiation [71]. Since
preadipocytes that are present in adipose tissue have the abil-
ity to diﬀerentiate towards macrophage-type cells and to-
wards adipocytes depending on the local environment [81],
the role of PPARγ in determining the fate of preadipocytes is
of interest. It can be hypothesized that activation of PPARγ
might favor adipocyte diﬀerentiation resulting in a decreased
inflammatory status of adipose tissue during obesity.
4.2. PPARγ and atheroslerosis
PPARγ is expressed in white blood cells and diﬀerentiated
macrophages and has been implicated in the process of
atherosclerosis. Initially, PPARγ activation was proposed to
be proatherogenic by stimulating uptake and storage of ox-
idized lipids in macrophages via upregulation of the scav-
enger receptor/fatty acid transporter CD36. This process
leads to foam cell development and is a key event in the
development of atherosclerosis [82]. In contrast, treatment
with thiazolidinediones has been shown to reduce the de-
velopment of atherosclerosis in mouse models [50, 71],
suggesting that PPARγ is antiatherogenic. The inhibitory
eﬀect on atherosclerosis may be mediated by upregulat-
ing expression of the ABCA1 transporter in macrophages,
thereby promoting cholesterol eﬄux. Furthermore, PPARγ
activation strongly reduces inflammatory gene expression in
macrophages, including MCP-1, VCAM-1, ICAM-1, IFNγ,
and TNFα [50]. Several human studies also point to an-
tiatherogenic eﬀects of PPARγ in type II diabetic patients.
Daily administration of 400mg troglitazone or 30mg pi-
oglitazone for 6 months resulted in a reduction of common
carotid arterial intimal and medial complex thickness which
is used as a noninvasive method to monitor early atheroscle-
rotic lesions [83, 84]. In a randomized controlled trial using
5238 patients with type II diabetes, treatment with 15mg to
45mg pioglitazone improved cardiovascular outcome [85].
Whether these protective eﬀects in humans are achieved by
inhibiting inflammation remains to be determined.
4.3. PPARγ and steatosis
It has been well established that in mouse models of steato-
sis, the development of fatty liver is associated with in-
creased hepatic expression of PPARγ. In a nonfatty liver,
the role of PPARγ appears to be limited and is proba-
bly restricted to stellate cell function during liver injury-
induced fibrogenesis [86]. During the development of steato-
sis, hepatocytes become lipid-loaden and gain phenotypical
characteristics of adipocytes which include the formation
of large lipid droplets. In parallel, expression of adipogenic
and lipogenic genes such as sterol regulatory element bind-
ing protein (SREBP), Adipose diﬀerentiation-related protein
(ADRP) and PPARγ are strongly upregulated in steatotic liv-
ers [87, 88]. Likely, the upregulation of PPARγ contributes
to the phenotype, since adenoviral-mediated hepatic overex-
pression of PPARγ1 on a PPARα −/− background dramat-
ically increases hepatic lipid accumulation and adipogenic
gene expression in mice [89]. Also, marked upregulation of
PPARγ in livers of PPARα −/−mice fed a high-fat diet leads
to increased expression of adipocyte markers and might con-
tribute to the fatty liver phenotype [43]. In contrast, mice
that specifically lack PPARγ in liver are protected from hep-
atic steatosis and show decreased expression levels of li-
pogenic genes compared to wild-type mice [73, 90]. Thus,
PPARγ induction appears to be necessary and suﬃcient for
hepatic steatosis.
The development of steatosis and progression into
steatohepatitis is closely linked to an increased inflamma-
tory state of the liver [4]. Recent data suggest that activa-
tion of PPARγ in fatty liver may protect against inflamma-
tion. Microarray analysis revealed that several inflammatory
genes that are upregulated in fatty livers of mice fed a high-fat
diet were strongly downregulated by PPARγ overexpression
in liver [89]. These genes include SAA, Chemokine (C-X-C
motif) ligand 10 (CXL10)/IP10 and interferon-γ-inducible
protein, 47 kd. Data from our own group showed that hep-
atic PPARγ activation by rosiglitazone under steatotic con-
ditions results in downregulation of multiple proinflamma-
tory genes. Thus, although activation of PPARγ in liver con-
tributes to the development of steatosis, inflammatory gene
expression is suppressed.
Several small clinical human studies have been per-
formed to evaluate the eﬀects of thiazolidinediones in pa-
tients diagnosed with NASH. After treatment, the degree of
steatosis and inflammation improved in a number of patients
indicating that PPARγ may be an interesting pharmacologi-
cal target [91]. Apart from weight gain, no side eﬀects were
reported in these studies. However, more studies are needed
to assess the potentially beneficial eﬀects of PPARγ activation
on liver function.
5. CONCLUSION
An elevated inflammatory status is increasingly believed to
be an important mediator that links excess (visceral) fat
mass with numerous metabolic abnormalities, including in-
sulin resistance. PPARs may influence the inflammatory re-
sponse either by direct transcriptional downregulation of
proinflammatory genes via mechanisms involving transre-
pression, or indirectly via their transcriptional eﬀects on lipid
metabolism. Numerous animal studies have demonstrated a
role for PPARs in counteracting obesity-induced inflamma-
tion in liver, adipose tissue, and the vascular wall. The ability
to reduce inflammatory cell infiltration further underlines
the central role of PPARs in obesity-induced inflammation
(Figure 1).
A growing number of studies strongly support anti-
inflammatory properties of PPARs in human obesity as
well. Several clinical trials in type II diabetic or hyperlipi-
demic patients have clearly shown that PPARα agonists in-
cluding fenofibrate, ciprofibrate, and gemfibrozil can eﬀec-
tively reduce circulating levels of TNFα, IL-6, fibrinogen,
and CRP [92]. Rosiglitazone, a selective PPARγ agonist, ex-
erts anti-inflammatory eﬀects in both obese and type II
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Figure 1: Central role of PPARs in obesity-induced inflammation. (Visceral) obesity and associated fatty liver stimulate inflammation in
adipose tissue and liver via increased recruitment and infiltration of macrophages, resulting in increased production of proinflammatory
cytokines. By downregulating proinflammatory genes in liver, adipose tissue and the vascular wall, PPARs have a major influence on the
progression of obesity-related inflammation and its complications.
diabetic individuals by decreasing plasma concentrations of
C-reactive protein, serum amyloid-A, and matrix metallo-
proteinase [93, 94].
Since synthetic PPARα and PPARγ agonists indepen-
dently ameliorate obesity-induced inflammation, agonists
that activate both PPARα and PPARγ (the so-called dual
PPARα/PPARγ agonists) might be even more eﬀective. Un-
fortunately, the development and clinical trials of these com-
pounds have been hampered by serious concerns regard-
ing their safety. Many dual PPARα/PPARγ agonists once in
clinical development have since been abandoned, often for
reasons of toxicity, including most recently the dual agonist
tesaglitazar.
In conclusion, although more work is needed to evaluate
their full potential in humans, especially in terms of safety,
PPAR agonists nevertheless represent a promising strategy to
mitigate obesity-associated inflammation.
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